Overview

Efficacy and Safety of Glimepiride as Oral Anti-Diabetic (OAD) Initiation Mono-therapy in Chinese Type 2 Diabetes Mellitus (T2DM)

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

To investigate the glycosylated hemoglobin (HbA1c) control of Glimepiride (AMARYL) as OAD initiation mono-therapy in type 2 diabetic patients in China.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Glimepiride
Hypoglycemic Agents